Privately-held PurMinds BioPharma (Burlington, Ontario, Canada), which specializes in developing therapies for neurodegenerative diseases, has completed a strategic equity investment in IMIO Life Ltd., a subsidiary of Tel Aviv–based Nextage Therapeutics Ltd. (TASE:NXTG). While IMIO Life Ltd. is focused on developing psychedelic-based therapeutics, PurMinds notes that its collaboration with the company will focus on optimizing…